Evidence map›Paper›PMID 30046528›Full record

ArticleInternational journal of ophthalmology2018

Alcohol delamination of the corneal epithelium for recurrent corneal erosion syndrome.

Áine Ní Mhéalóid, Taylor Lukasik, William Power, Conor C Murphy

Open access · goldAbstract read
In one paragraph

Article in International journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trigger Factors in Recurrent Corneal Erosion Syndrome.Journal of clinical medicine · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Áine Ní MhéalóidEducation and Research Centre, Royal Victoria Eye and Ear Hospital, Dublin D02XK51, Ireland.
Taylor LukasikSchool of Medicine, RCSI School of Medicine, Dublin D02VN51, Ireland.
William PowerOphthalmology Department, Royal Victoria Eye and Ear Hospital, Dublin D02XK51, Ireland.
Conor C MurphyEducation and Research Centre, Royal Victoria Eye and Ear Hospital, Dublin D02XK51, Ireland.
Royal Victoria Eye and Ear Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the outcomes of alcohol delamination (ALD) of the corneal epithelium for the treatment of recurrent corneal erosion syndrome (RCES) and to implement a standardized treatment protocol for this condition utilizing evidence based practice and the findings of an internal audit.

methodsA retrospective analysis of 42 eyes of 40 patients diagnosed with RCES who were treated with ALD between January 2006 and March 2016 was conducted. Patients had 20% alcohol applied to the cornea with the use of a well for 40s. Patients were reviewed one week later in the Outpatient Department. Outcome criteria were established based on standards from other studies in the medical literature. These included, a treatment success rate of at least 72% (defined as complete resolution of symptoms one month after treatment), a postoperative complication a rate of <5% (mainly infective keratitis, and subepithelial haze), and the absence of any detrimental effect on visual acuity in ≥95% of patients.

resultsThe mean age at the time of ALD was 41.17±13.44y. Patients were followed for an average of 12.8±15.65mo. The majority were female (52.5%,

conclusionALD is an efficacious and cost-effective primary surgical intervention for RCES.

Indexed as

alcohol delaminationcorneal abrasioncorneal dystrophycorneal traumarecurrent corneal erosion

Identifiers

PMID30046528
PMCPMC6048330
OpenAlexW2912425369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.